EMPOWERING DENDRITIC CELLS

DENDRITIC CELLS TO TREAT CANCER

Amphera B.V., a clinical stage Dutch life science company, develops dendritic cell therapies for the treatment of cancer. Our lead indication is mesothelioma, a cancer of the lining of the lungs. MesoPher is autologous dendritic cells loaded with our proprietary allogeneic tumour cell lysate PheraLys. PheraLys is a well-characterised, innovative source of a broad-spectrum of Tumour Associated Antigens. Several clinical studies with our lead product candidate MesoPher are ongoing.

MEET US AT

7-10 January 2019
JP Morgan – San Francisco

25-27 March 2019
Bio Europe Spring – Vienna

3-6 June 2019
Bio International
Convention – Philadelphia